EGFR and non-small cell lung carcinoma: The LUX-Lung 2 was a single arm phase II trial that assessed activity of two doses of afatinib (40 mg and 50 mg daily) as first- or second-line treatment in 129 NSCLC patients harboring EGFR mutations.